ORIGINAL RESEARCH—PEYRONIE'S DISEASE Use of Penile Extender Device in the Treatment of Penile Curvature as a Result of Peyronie's Disease. Results of a Phase II Prospective Study

Published on Feb 1, 2009in The Journal of Sexual Medicine3.649
· DOI :10.1111/j.1743-6109.2008.01108.x
Paolo Gontero32
Estimated H-index: 32
(UNITO: University of Turin),
Massimiliano Di Marco3
Estimated H-index: 3
+ 4 AuthorsNicola Mondaini29
Estimated H-index: 29
(UniFI: University of Florence)
Introduction. Pilot experiences have suggested that tension forces exerted by a penile extender may reduce penile curvature as a result of Peyronie's disease. Aim. To test this hypothesis in a Phase II study using a commonly marketed brand of penile extender. Methods. Peyronie's disease patients with a curvature not exceeding 50° with mild or no erectile dysfunction (ED) were eligible. Fifteen patients were required to test the efficacy of the device assuming an effect size of >0.8, consistent with an "important" reduction in penile curvature. Changes in penile length over baseline and erectile function (EF) domain scores of the International Index of Erectile Function (IIEF) constituted secondary end points. Main Outcome Measures. Patients were counselled on the use of the penile extender for at least 5 hours per day for 6 months. Photographic pictures of the erect penis and measurements were carried out at baseline, at 1, 3, 6, and 12 months (end of study). The IIEF-EF domain scores were administered at baseline and at the end of study. Treatment satisfaction was assessed at end of study using a nonvalidated institutional 5-item questionnaire. Results. Penile curvature decreased from an average of 31° to 27° at 6 months without reaching the effect size (P = 0.056). Mean stretched and flaccid penile length increased by 1.3 and 0.83 cm, respectively at 6 months. Results were maintained at 12 months. Overall treatment results were subjectively scored as acceptable in spite of curvature improvements, which varied from "no change" to "mild improvement." Conclusions. In our study, the use of a penile extender device provided only minimal improvements in penile curvature but a reasonable level of patient satisfaction, probably attributable to increased penile length. The selection of patients with a stabilized disease, a penile curvature not exceeding 50°, and no severe ED may have led to outcomes underestimating the potential efficacy of the treatment. Gontero P, Di Marco M, Giubilei G, Bartoletti R, Pappagallo G, Tizzani A, and Mondaini N. Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study. J Sex Med 2009;6:558- 566.
  • References (51)
  • Citations (90)
📖 Papers frequently viewed together
98 Citations
242 Citations
137 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
Summary. Micropenis should be diagnosed shortly after birth and differentiated from associated deformities and syndromes. Calling in a paediatric endocrinologist and a geneticist is obligatory. Endocrine treatment should be undertaken in the second and third months (25 mg testosterone enanthate per month) after a positive HCG test. Where there is a negative endocrine response and/or associated sex differentiation derangement, a sex change operation towards female should be discussed with the fam...
21 CitationsSource
#1E. Austoni (University of Milan)H-Index: 1
#2A. Guarneri (University of Milan)H-Index: 1
Last. G. Gatti (University of Milan)H-Index: 1
view all 3 authors...
Summary. Penile lengthening and thickening techniques can be performed in different ways for treatment of congenital penile h^poplasia and dysmorphophobia in terms of aesthetics or function. Particularly for penile lengthening, a combination of surgery and stretcher device is suggested. Surgery for lengthening comprises three different stages; suture with plane alternating edges of the pubo-penile skin, infrapubic lipectomy, and section of the suspensory ligament. Our approach to penile thickeni...
16 CitationsSource
#1Paolo Gontero (UNITO: University of Turin)H-Index: 32
#2Massimiliano Di Marco (UNITO: University of Turin)H-Index: 3
Last. Nicola Mondaini (UNITO: University of Turin)H-Index: 29
view all 7 authors...
OBJECTIVE To assess a commonly marketed brand of penile extender, the Andro-Penis® (Andromedical, Madrid, Spain), widely used devices which aim to increase penile size, in a phase II single-arm study powered to detect significant changes in penile size, as despite their widespread use, there is little scientific evidence to support their potential clinical utility in the treatment of patients with inadequate penile dimensions. PATIENTS AND METHODS Fifteen patients were required to test the effic...
36 CitationsSource
#1James F. Smith (UCSF: University of California, San Francisco)H-Index: 27
#2Thomas J. Walsh (UCSF: University of California, San Francisco)H-Index: 15
Last. Tom F. Lue (UCSF: University of California, San Francisco)H-Index: 83
view all 5 authors...
ABSTRACT Introduction Peyronie's disease (PD) occurs in 3–9% of all men. Little is known regarding the specific psychological or emotional disruptions to sexuality associated with PD. Aim Our primary aim was to identify risk factors associated with psychosocial difficulties in men with PD. Methods This cross‐sectional study enrolled patients from a single clinical practice. Detailed medical histories, physical examinations, and a PD‐specific questionnaire were used to define clinical characteris...
102 CitationsSource
#1Raymond C. RosenH-Index: 99
#2Joseph A. Catania (OSU: Oregon State University)H-Index: 59
Last. Laurence A. Levine (Rush University Medical Center)H-Index: 51
view all 7 authors...
ABSTRACT Introduction There are no validated scales for assessing the psychosocial impact of Peyronie's disease (PD), which affects approximately 5–10% of men over age 50. Aim To develop a psychometrically valid outcome measure for assessing psychosocial and sexual consequences of PD. To conduct a qualitative study of men with PD and age‐matched controls, and design a new patient‐reported outcome measure of PD. Methods An expert advisory panel identified relevant topics and conceptual areas to b...
122 CitationsSource
#1Laurence A. Levine (Rush University Medical Center)H-Index: 51
#2Mark M NewellH-Index: 2
Last. Frederick L. Taylor (Rush University Medical Center)H-Index: 7
view all 3 authors...
98 CitationsSource
#1Anthony J Bella (U of O: University of Ottawa)H-Index: 25
#2Michael A. Perelman (Cornell University)H-Index: 25
Last. Tom F. Lue (UCSF: University of California, San Francisco)H-Index: 83
view all 4 authors...
ABSTRACT Introduction The management of Peyronie's disease (PyD) presents several challenges to the clinician. Despite progress in the understanding of PyD on several fronts, it remains a physically and psychologically devastating condition for the affected patient and partner. Aim The purpose of this Continuing Medical Education article is to review contemporary knowledge of the epidemiology, pathophysiology, evaluation, and management of PyD, thus enabling best-practice management. Methods An ...
93 CitationsSource
#1Shane Russell (NU: Northwestern University)H-Index: 3
#2William D. Steers (Department of Urology, University of Virginia)H-Index: 53
Last. Kevin T. McVary (NU: Northwestern University)H-Index: 50
view all 3 authors...
Abstract Objective We evaluated the peer-reviewed urology literature for intraplaque injection of medication for Peyronie's disease and assessed the quality of studies via rigorous evidence-based medicine criteria. Methods We performed a search of peer-reviewed literature looking at all agents used to treat Peyronie's disease by intraplaque injections. These were then evaluated using the Oxford Centre for Evidence-Based Medicine criteria, which ranks studies from strongest (level 1) to weakest (...
43 CitationsSource
#1Michael Ohebshalom (Cornell University)H-Index: 9
#2John P. Mulhall (Cornell University)H-Index: 60
Last. Marilyn Parker (Loyola University Medical Center)H-Index: 23
view all 4 authors...
ABSTRACT Aim Peyronie’s disease (PD) may be treated in a medical or surgical fashion. Factors involved in the decision of which treatment to choose include duration of disease and magnitude of penile deformity. Curvature can be measured using at‐home photography (AHP), vacuum erection device (VED), or intracavernosal injection (ICI). This study was undertaken to determine the concordance between the three methods of deformity assessment. Patients were also questioned regarding the presence of er...
63 CitationsSource
79 CitationsSource
Cited By90
BACKGROUND: Peyronie's disease is an inflammatory disorder of the penis, where scar tissue creates a plaque at the level of the albuginea, limits its extension, and leads to a bent and shorter penis during erections. There are no international standards for the evaluation and the treatment of the disease. The aim of this article is to review the current knowledge about the management of Peyronie's disease and to suggest an algorithm to help physicians evaluate and manage this condition. MATERIAL...
#1Matthew J. Ziegelmann (Rush University Medical Center)H-Index: 9
#2Petar Bajic (Rush University Medical Center)H-Index: 1
Last. Laurence A. Levine (Rush University Medical Center)H-Index: 51
view all 3 authors...
Peyronie's disease is a common yet poorly understood condition characterized by penile pain, curvature, sexual dysfunction and psychological bother. Peyronie's disease represents a penile wound healing disorder, and is thought to arise from exuberant scarring in response to penile trauma in genetically predisposed men. In the absence of active treatment, the majority of men experience stable or worsening symptoms, with few reporting spontaneous resolution in penile curvature or other deformity. ...
1 CitationsSource
#1R. Bole (Mayo Clinic)H-Index: 2
#2Lindsay A. White (Mayo Clinic)
Last. Matthew J. Ziegelmann (Mayo Clinic)H-Index: 9
view all 6 authors...
Peyronie’s disease (PD)-related penile deformity is managed with multiple treatment modalities including oral medications, intralesional injections, and surgery. Penile traction therapy (PTT) is one such modality with purported benefits, albeit with notable differences in the characteristics of available traction devices and published study protocols. We provide a comprehensive review of the available data supporting PTT for PD treatment. We performed a rigorous database search to identify all s...
#1Jesse Ory (Dal: Dalhousie University)
Last. Gavin M. LangilleH-Index: 4
view all 3 authors...
Abstract Introduction Evidence for noninvasive management of Peyronie’s disease contains many options with varying levels of evidence for each. Many first-line treatments recommended by urologists lack strong evidence for their use. Aim We summarize the noninvasive (oral medications, topical medications, traction, vacuum erection devices, extracorporeal shock wave therapy, intracavernosal injections and electromotive therapy) treatment options for Peyronie’s disease and provide the levels of evi...
#1Gabriele Antonini (Policlinico Umberto I)H-Index: 15
#2Ettore De Berardinis (Policlinico Umberto I)H-Index: 12
Last. Paul PeritoH-Index: 12
view all 13 authors...
Penile shortening after inflatable penile prosthesis for erectile dysfunction is a common postoperative patient complaint and can reduce overall satisfaction with the procedure. In this prospective study we report our results regarding penile dimensions and patient satisfaction outcomes after 1 year of follow-up from AMS™LGX700® penile prosthesis implant with 6 months of vacuum erectile device therapy. Seventy-four selected patients with medically refractory erectile dysfunction underwent AMS™ L...
1 CitationsSource
#1Matthew J. Ziegelmann (Mayo Clinic)H-Index: 9
#2Landon Trost (Mayo Clinic)H-Index: 16
Last. Laurence A. Levine (Rush University Medical Center)H-Index: 51
view all 3 authors...
While surgery remains the gold standard for the treatment of penile deformity associated with Peyronie’s disease, various non-surgical options including oral and topical agents, penile traction, and intralesional injections are available with varying levels of evidence and treatment efficacy seen in the literature. Herein we review various non-surgical managements for Peyronie’s disease and describe our techniques for intralesional injections with verapamil and Collagenase Clostridium histolytic...
#1Dyvon T. Walker (UCLA: University of California, Los Angeles)
#1Dyvon Walker (UCLA: University of California, Los Angeles)
Last. Jesse N. Mills (UCLA: University of California, Los Angeles)H-Index: 4
view all 5 authors...
Purpose of Review The goal of this article is to review the current management options for Peyronie’s disease (PD), focusing on the acute phase of the disease. Additionally, we aim to highlight the most recent literature on the subject.
Peyronie’s disease is a condition that causes abnormal healing of the tunica albuginea, causing penile curvature. It is difficult to treat and its management is continuing to evolve. Proposed non-surgical treatments have included oral, topical, intralesional, extracorporeal shockwave, and traction therapy. The study of Peyronie’s disease is made difficult by heterogeneity in the timing of presentation, severity and characteristics of deformity, and associated complaints. Moreover, meta-analyses ...
#1Kiran L. Sharma (Mayo Clinic)H-Index: 1
#2Manaf Alom (Mayo Clinic)H-Index: 4
Last. Landon Trost (Mayo Clinic)H-Index: 16
view all 3 authors...
Purpose of Review To summarize data on lengthening treatments from PubMed-indexed scientific publications.
#1Ahmed M.S. Ibrahim (McGill University)H-Index: 16
#1Ahmed Ibrahim (McGill University)H-Index: 6
Last. Serge Carrier (McGill University)H-Index: 30
view all 6 authors...
Abstract Introduction Currently, there are several treatment options for Peyronie disease (PD). Although surgical interventions have better reported outcomes than conservative therapy, surgery is not suitable for all patients with PD. Therefore, oral therapy for PD is still a frequently used treatment due to low cost, convenience and limited side effects. However, current literature on the efficacy of oral therapy in PD is inconclusive. Pentoxifylline and colchicine have both shown some promise ...